Overview

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Phase:
PHASE2
Details
Lead Sponsor:
Ferrer Internacional S.A.